Deciding whether Keros Therapeutics represents a buy or sell depends heavily on an investor's individual risk tolerance, time horizon, and portfolio strategy regarding clinical-stage biotechnology equities. Wall Street analysts tracking the biopharmaceutical sector generally maintain favorable consensus views based on the clinical potential of its novel protein therapeutics targeting rare and severe disorders. However, because the company is pre-revenue and depends heavily on successful clinical trials, regulatory clearances, and future capital requirements, it carries inherent high volatility. Investors comfortable with high-risk growth opportunities often view it as a speculative buy, whereas risk-averse investors might consider it too volatile until commercial products reach the market.